Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Dan Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2755-7258; OpenAlex author ID A5101213945, A5111276112. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 6 papers

Papers 10

  1. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  2. Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation … Last author DOI 10.1136/jitc-2026-015705↗
  3. Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Last author DOI 10.1158/1078-0432.ccr-26-1824↗
  4. Impact of adding recurrence/metastasis-directed therapy to systemic therapy in postoperative recurrent or metastatic pancreatic adenocarcinoma: a retrospective… Last author DOI 10.1177/17588359261417639↗
  5. Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for rec… Co-author DOI 10.3389/fimmu.2026.1817221↗
  6. Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory t… Co-author DOI 10.3389/fphar.2026.1805590↗
  7. RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1↗
  8. Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case report and literature review. Last author DOI 10.3389/fphar.2025.1656670↗
  9. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic ad… Last author DOI 10.1136/bmjopen-2024-084274↗
  10. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1093/oncolo/oyac146↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chenyan Zhang · 5 shared papers, 2024–2026 · strength 1.32
  2. Huanji Xu · 4 shared papers, 2025–2026 · strength 1.25
  3. Ke Cheng · 5 shared papers, 2023–2026 · strength 0.98
  4. Xiaorui Zhu · 3 shared papers, 2025–2026 · strength 0.79
  5. Junjie Xiong · 4 shared papers, 2023–2026 · strength 0.75
  6. Chen Chang · 3 shared papers, 2023–2026 · strength 0.54
  7. Xiaoying Li · 2 shared papers, 2025–2026 · strength 0.46
  8. Xin Wang · 1 shared paper, 2026 · strength 0.43
  9. Ke Cheng · 1 shared paper, 2025 · strength 0.37
  10. Zixing Huang · 2 shared papers, 2025–2026 · strength 0.36
  11. Yi Cheng · 2 shared papers, 2025–2026 · strength 0.36
  12. Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
  13. Wanting Hou · 2 shared papers, 2025–2026 · strength 0.36
  14. Yu Li · 1 shared paper, 2026 · strength 0.30
  15. Haopeng Yu · 1 shared paper, 2026 · strength 0.30
  16. Yuqi Wang · 1 shared paper, 2026 · strength 0.30
  17. Wei Li · 1 shared paper, 2026 · strength 0.23
  18. Chunyi Hao · 1 shared paper, 2026 · strength 0.23
  19. Haitao Zhang · 1 shared paper, 2026 · strength 0.23
  20. Guang Tan · 1 shared paper, 2026 · strength 0.23
  21. Liwei Wang · 1 shared paper, 2026 · strength 0.23
  22. Jianhui Wu · 1 shared paper, 2026 · strength 0.23
  23. Jiujie Cui · 1 shared paper, 2026 · strength 0.23
  24. Kuirong Jiang · 1 shared paper, 2026 · strength 0.23
  25. Qi Li · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.